$RHE Regional Health Properties CEO Brent Morrison has demonstrated notable confidence in the company by consistently purchasing shares with his own capital in the open market. According to recent SEC filings, Morrison now owns approximately 331,771 common shares, including shares held through his IRA account, making him one of the company's largest individual shareholders.
Based on an estimated 3.75–3.80 million shares outstanding, Morrison's ownership stake is approximately 8.7%–8.9% of the company. This is a significant insider position for a micro-cap company and closely aligns management's interests with those of shareholders.
What makes these purchases particularly noteworthy is that they were open-market transactions funded with personal cash, rather than option exercises or stock-based compensation. In early June alone, Morrison invested nearly $28,000 of his own money by purchasing common shares and Series D Preferred Stock.......
$RHE One of the more encouraging recent developments at Regional Health Properties is that CEO Brent Morrison has been buying shares with his own money in the open market. In early June, he purchased 10,000 common shares at $1.18, another 5,000 common shares at $1.15, and 5,000 shares of the Series D Preferred Stock at $2.02. In total, he invested nearly $28,000 of personal capital.
$RHE The current situation is significantly better than it was in 2024. The most important development is that revenue growth is now becoming visible following the SunLink transaction, while the CEO is actively purchasing shares. The next major catalyst could be the company's second-quarter 2026 earnings report, expected around August. If the company demonstrates further improvement in EBITDA and cash flow, that would be far more important than any press release.
$RHE https://www.marketscreener.com/news/regional-health-properties-inc-reports-earnings-results-for-the-first-quarter-ended-march-31-2026-ce7f5bd3de88f62c?utm_source=chatgpt.com
Regional Health Properties Inc. just reported a major revenue jump in Q1 2026 following the SunLink merger, with quarterly revenue increasing from roughly $7.2M to more than $21M.X year-over-year. The company is clearly transforming from a small healthcare real estate story into a broader integrated healthcare and pharmacy operation. Balance sheet pressure still remains significant with elevated debt levels and limited cash reserves, so this is not a low-risk setup, but the operational scale-up is becoming visible in the numbers. The market will likely focus on whether management can convert this revenue expansion into sustainable positive cash flow over the coming quarters.
$RHE The white dashed lines on the chart indicate the price targets. Based on the report, RHEP has strong fundamental potential — the current 5x P/E ratio is significantly below the healthcare sector average. The $3–5 range appears to be a realistic mid-term target if the market recognizes the results.
$RHE The core operations are moving in the right direction. Patient care revenue increased to $36.1 million from $11.3 million, and $11.7 million in pharmacy revenue also appeared, indicating that the SunLink deal has genuinely reshaped the revenue mix.
$RHE The headline numbers are strong: in 2025, revenue increased to $53.2 million from $18.3 million in 2024, while net income came in at $3.37 million compared to a $3.22 million loss previously. In Q4, a similar jump is visible, with $20.8 million in revenue and $2.7 million in net income.
$RHE ~$4–5M market cap, OTC inefficiency, and improving fundamentals. That’s the kind of combination where even a small shift in sentiment or liquidity can reprice the stock aggressively.
If they can convert earnings into consistent operating cash flow and keep deleveraging, this can move from “distressed microcap” to “early recovery play” very fast.
This is still risky, but from a bull perspective, it’s exactly the kind of underfollowed turnaround where the upside comes from multiple expansion + execution, not hype.
$RHE RHEP is starting to look like a classic microcap turnaround that the market hasn’t priced yet. The latest numbers show real improvement, not just accounting noise. Revenue is scaling, margins are stabilizing, and most importantly, they printed positive net income and EPS, which is rare at this size.
The SunLink merger is clearly doing its job. Occupancy jumped meaningfully, patient volumes are rising, and the payer mix is improving — that’s exactly what you want to see in a healthcare RE/ops hybrid. This isn’t just top-line growth, it’s quality of revenue improving, which typically leads to better cash flow over time.
On capital structure, buying back preferred shares at a discount is a strong signal. Management is effectively deleveraging in a smart way, reducing future dilution pressure and cleaning up the balance sheet without burning full cash value.
$RHE On the operational side, the picture is improving. According to management, the SunLink merger has significantly expanded the platform. Portfolio occupancy increased from 62.5% to 72.2% year-over-year, while in the HealthCare Services segment, Average Daily Census rose from 389 to 467, and the quality mix improved from 9.1% to 12.2%. In addition, the company sold a non-core asset, the Coosa Valley facility, realizing a $2.7 million gain.
From a capital structure perspective, there has also been movement. The company repurchased 511,099 shares of Series B preferred stock at a discount, which is a positive signal for shareholders as it shows management is attempting to reduce the preferred equity burden at an attractive price. However, the balance sheet is still not clean: total debt stood at $44.0 million at year-end, and the company reported $2.3 million in operating cash outflow for 2025. So despite generating a profit, the cash flow profile is not yet fully convincing.
$RHE https://www.globenewswire.com/news-release/2026/04/07/3269368/0/en/Regional-Health-Properties-Reports-Fourth-Quarter-2025-Results.html
Based on the latest market information, Regional Health Properties Inc. is now trading on the OTCQB under the ticker RHEP, and the recently released Q4 2025 and full-year 2025 results are the main near-term catalyst for the stock.
For full-year 2025, the company reported $53.2 million in revenue, $3.4 million in GAAP net income, and $1.09 in EPS. In the fourth quarter alone, revenue came in at $20.8 million, with $2.7 million in net income and $0.68 in EPS.
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Valuation
Trading at 0.2× sales vs its 0.2× historical median P/S.
Fair value ≈ $2.63 · price $2.77 today
Overvalued · 5% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
